How The Travere Therapeutics (TVTX) Story Is Shifting After FSGS Approval And Split Analyst Views

Travere Therapeutics just saw its modeled fair value per share move slightly, from US$42.36 to US$42.50, in the latest analyst update. That modest shift sits against a backdrop of Street research ...

Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock?

Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Fierce Pharma

Travere maps course for Filspari's $3B US opportunity after landmark rare disease nod

With the path to blockbusterland now in sight, Travere Therapeutics is ready to hit the ground running after Monday’s ...
STAT

Travere’s drug for a kidney disease doesn’t improve kidney function. The FDA approved it anyway

This week, the FDA flexed its regulatory authority to approve the first medicine to treat focal segmental glomerulosclerosis, ...
BioSpace

Travere’s Filspari overcomes Phase 3 fail to become first drug for rare kidney disease

The FDA has greenlit Travere Therapeutics’ Filspari as the only available treatment for focal segmental glomerulosclerosis ...

Travere, Ligand Pharma announce FDA label expansion for Filspari

Travere Therapeutics (TVTX) stock and Ligand Pharmaceuticals (LGND) stock gain on FDA label expansion for Filspari. Read more ...

Travere Therapeutics gains FDA approval for sparsentan in FSGS

Travere Therapeutics has received the US Food and Drug Administration (FDA) full approval for Filspari (sparsentan) to reduce ...
Fierce Pharma

Despite uncertainties, Travere’s Filspari emerges as first FDA-approved FSGS treatment

Monday’s FDA approval makes Filspari the first therapy specifically indicated for FSGS, a condition that represents a $1 ...
pharmaphorum

Travere claims first FDA OK in rare kidney disease FSGS

Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare ...

Travere Wins FDA Approval for FILSPARI in FSGS

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics Shares Rise on FDA Approval of Kidney-Disorder Drug

Travere Therapeutics shares surged in premarket trading after the company received regulatory approval in the U.S. for its rare kidney-disorder treatment. Shares trading in premarket rose 37% to ...

Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS Transcript

Good afternoon, and welcome to the Travere Therapeutics Business Update Conference Call. Today's call is being recorded. At this time, I would like to turn the conference call over to Nivi Nehra, Vice ...